Biotechnology company Bicycle Therapeutics has announced the appointment of Sir Keith Peters FRS to chairman of the firm’s scientific advisory board.
Sir Peters is Emeritus Regius Professor of Physic at the University of Cambridge, where he was also head of the School of Clinical Medicine.
He is a fellow of the Royal Society, and fellow and past president of the Academy of Medical Sciences.
His industry experience includes membership of The Board of Advisers to Merck Research Laboratories and Senior Consultant in R&D to GlaxoSmithKline.
In the BioTech sector, he was a longstanding member of the scientific advisory board of Cambridge Antibody Technology. Prior to working in industry, Sir Peters held a number of academic appointments, including posts at the University of Birmingham, the National Institute for Medical Research at Mill Hill and the Welsh National School of Medicine.
The firm is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles for diseases that are underserved by existing therapeutics.
Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in the US. “Sir Keith is a world-renowned expert in the field of clinical immunology and has made significant contributions to the development of new medicines by applying a better understanding of physiology to the development of novel therapies,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
“In addition, Sir Keith has been a torch bearer for clinical research through the assembly of cutting-edge academic research departments at a number of leading medical institutions. We thank our outgoing Chairman, Jose Carlos, for his excellent leadership of the Scientific Advisory Board over the last several years and are honored to now have Sir Keith serve as the Board’s new Chair.”
Sir Peters said of the appointment: “I’ve served on Bicycle’s Scientific Advisory Board since its inception and in that time, have been impressed by the tremendous progress the company has made in applying its innovative technology to develop novel therapeutic candidates,” said Sir Keith Peters, Chairman of the Scientific Advisory Board.
“I look forward to continuing to work with senior leadership to advance the Company’s growing pipeline of clinical assets in this new expanded capacity.”